Fahy Bridget N, Tang Laura H, Klimstra David, Wong W Douglas, Guillem Jose G, Paty Philip B, Temple Larissa K F, Shia Jinru, Weiser Martin R
Department of Surgery, Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Ann Surg Oncol. 2007 Feb;14(2):396-404. doi: 10.1245/s10434-006-9197-3. Epub 2006 Nov 9.
Predicting rectal carcinoid behavior exclusively on the basis of tumor size is imprecise. We sought to identify factors associated with outcome and incorporate them into a preoperative risk stratification scheme.
Seventy patients with rectal carcinoid evaluated at our institution were identified. Demographic, clinical, and histopathologic data were collected and correlated with recurrence and survival.
The mean age of our cohort was 53.6 years. Fifty-seven percent of patients were women. The mean tumor size was 1.3 cm (range, .1-5 cm). Twenty-five percent of patients had deeply invasive tumors (into the muscularis propria or deeper); an equal percentage had tumors with lymphovascular invasion (LVI) or an increased mitotic rate (two or more mitoses per 50 high-power fields). Eleven patients (17%) had distant metastases at presentation. Sixty-one patients were followed for a median of 22 months (range, 2-308 months), during which seven patients developed recurrence and seven died of disease (including two of seven whose disease recurred). Poor outcome was associated with large tumor size, deep invasion, presence of LVI, and increased mitotic rate. These factors were incorporated into a Carcinoid of the Rectum Risk Stratification (CaRRS) score. CaRRS predicted recurrence-free and disease-specific survival better than any single factor alone.
Poor prognostic features of rectal carcinoids include large size, deep invasion, LVI, and increased mitotic rate. The CaRRS score incorporates these features and accurately predicts outcome. Because the CaRRS score is based on values available by preoperative biopsy, it can identify patients with favorable prognosis and those with poor prognosis who may benefit from additional staging or surveillance.
仅基于肿瘤大小来预测直肠类癌的行为并不精确。我们试图确定与预后相关的因素,并将其纳入术前风险分层方案。
确定了在我们机构接受评估的70例直肠类癌患者。收集了人口统计学、临床和组织病理学数据,并将其与复发和生存情况相关联。
我们队列的平均年龄为53.6岁。57%的患者为女性。平均肿瘤大小为1.3厘米(范围为0.1 - 5厘米)。25%的患者有深度浸润性肿瘤(侵犯固有肌层或更深);相同比例的患者有肿瘤伴有淋巴管侵犯(LVI)或有丝分裂率增加(每50个高倍视野有两个或更多有丝分裂)。11例患者(17%)在就诊时已有远处转移。61例患者接受了中位时间为22个月(范围为2 - 308个月)的随访,在此期间,7例患者出现复发,7例患者死于疾病(包括7例复发患者中的2例)。预后不良与肿瘤大小、深度浸润、LVI的存在以及有丝分裂率增加有关。这些因素被纳入直肠类癌风险分层(CaRRS)评分。CaRRS对无复发生存和疾病特异性生存的预测比任何单一因素都更好。
直肠类癌的不良预后特征包括肿瘤大、深度浸润、LVI和有丝分裂率增加。CaRRS评分纳入了这些特征并准确预测预后。由于CaRRS评分基于术前活检可获得的值,它可以识别预后良好的患者以及可能从额外分期或监测中获益且预后不良的患者。